ES2217956B1 - Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. - Google Patents

Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Info

Publication number
ES2217956B1
ES2217956B1 ES200300172A ES200300172A ES2217956B1 ES 2217956 B1 ES2217956 B1 ES 2217956B1 ES 200300172 A ES200300172 A ES 200300172A ES 200300172 A ES200300172 A ES 200300172A ES 2217956 B1 ES2217956 B1 ES 2217956B1
Authority
ES
Spain
Prior art keywords
pyrimidin
carbonitrile
methyl
amino
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200300172A
Other languages
English (en)
Spanish (es)
Other versions
ES2217956A1 (es
Inventor
Emma Terricabras Belart
Victor Manuel Segarra Matamoros
Julio Alvarez-Builla Gomez
Juan Jose Vaquero Lopez
Jose Miguel Minguez Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200300172A priority Critical patent/ES2217956B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to DE602004007239T priority patent/DE602004007239T2/de
Priority to EP04704579A priority patent/EP1590352B1/en
Priority to US10/542,940 priority patent/US7662814B2/en
Priority to CN200480007362A priority patent/CN100582112C/zh
Priority to AT04704579T priority patent/ATE365742T1/de
Priority to ES04704579T priority patent/ES2289475T3/es
Priority to JP2006500010A priority patent/JP2006515604A/ja
Priority to PCT/EP2004/000584 priority patent/WO2004065391A1/en
Publication of ES2217956A1 publication Critical patent/ES2217956A1/es
Application granted granted Critical
Publication of ES2217956B1 publication Critical patent/ES2217956B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES200300172A 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. Expired - Fee Related ES2217956B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES200300172A ES2217956B1 (es) 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP04704579A EP1590352B1 (en) 2003-01-23 2004-01-23 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
US10/542,940 US7662814B2 (en) 2003-01-23 2004-01-23 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors
CN200480007362A CN100582112C (zh) 2003-01-23 2004-01-23 用作PDE7抑制剂的4-氨基噻吩并[2,3-d]嘧啶-6-甲腈衍生物
DE602004007239T DE602004007239T2 (de) 2003-01-23 2004-01-23 4-AMINOTHIENO[2,3-d] PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7-INHIBITOREN
AT04704579T ATE365742T1 (de) 2003-01-23 2004-01-23 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
ES04704579T ES2289475T3 (es) 2003-01-23 2004-01-23 Derivados de l-aminotieno(2,3-d)pirimidina-6-carbonitrilo como inhibidores de pde7.
JP2006500010A JP2006515604A (ja) 2003-01-23 2004-01-23 Ｐｄｅ７阻害剤としての４−アミノチエノ［２，３−ｄ］ピリミジン−６−カルボニトリル誘導体
PCT/EP2004/000584 WO2004065391A1 (en) 2003-01-23 2004-01-23 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200300172A ES2217956B1 (es) 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Publications (2)

Publication Number Publication Date
ES2217956A1 ES2217956A1 (es) 2004-11-01
ES2217956B1 true ES2217956B1 (es) 2006-04-01

Family

ID=32749101

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200300172A Expired - Fee Related ES2217956B1 (es) 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES04704579T Expired - Lifetime ES2289475T3 (es) 2003-01-23 2004-01-23 Derivados de l-aminotieno(2,3-d)pirimidina-6-carbonitrilo como inhibidores de pde7.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04704579T Expired - Lifetime ES2289475T3 (es) 2003-01-23 2004-01-23 Derivados de l-aminotieno(2,3-d)pirimidina-6-carbonitrilo como inhibidores de pde7.

Country Status (8)

Country Link
US (1) US7662814B2 (https=)
EP (1) EP1590352B1 (https=)
JP (1) JP2006515604A (https=)
CN (1) CN100582112C (https=)
AT (1) ATE365742T1 (https=)
DE (1) DE602004007239T2 (https=)
ES (2) ES2217956B1 (https=)
WO (1) WO2004065391A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610774A4 (en) * 2003-04-09 2008-07-16 Exelixis Inc TIE-2 MODULATORS AND METHODS OF USE
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
EP1806347A4 (en) * 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20090247554A1 (en) * 2006-03-30 2009-10-01 Takeda San Diego, Inc. Kinase inhibitors
TWI498332B (zh) 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
EP2043654A2 (en) * 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thienopyrimidines useful as modulators of ion channels
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
ES2571028T3 (es) * 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
US20100093714A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
CA2772371A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN102459272B (zh) * 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
AU2011281015B2 (en) 2010-07-23 2015-09-24 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
NZ628054A (en) 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
ES2575143T3 (es) 2011-11-23 2016-06-24 Cancer Research Technology Limited Inhibidores de tienopiridina de la proteína quinasa C atípica
WO2013112699A2 (en) * 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CA2861464C (en) * 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
AR092707A1 (es) 2012-09-28 2015-04-29 Takeda Pharmaceuticals Co Metodo de produccion de derivado de tienopirimidina
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN108135906A (zh) * 2015-07-24 2018-06-08 路易斯维尔大学研究基金会有限公司 治病化合物、组合物、方法、及化合物制备方法
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN115232146A (zh) * 2022-08-04 2022-10-25 山东大学 一种2-氨基噻吩并[2,3-d]嘧啶类化合物及其制备方法和应用
IL318817A (en) 2022-08-18 2025-04-01 Mitodicure Gmbh Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728759A1 (en) * 1995-02-24 1996-08-28 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US6130223A (en) * 1996-10-24 2000-10-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyrimidine with phosphodiesterase V inhibiting effect
EP1329454A1 (en) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
JPH1087492A (ja) * 1996-06-25 1998-04-07 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728759A1 (en) * 1995-02-24 1996-08-28 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US6130223A (en) * 1996-10-24 2000-10-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyrimidine with phosphodiesterase V inhibiting effect
EP1329454A1 (en) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both

Also Published As

Publication number Publication date
ES2217956A1 (es) 2004-11-01
ATE365742T1 (de) 2007-07-15
EP1590352B1 (en) 2007-06-27
CN1761671A (zh) 2006-04-19
US7662814B2 (en) 2010-02-16
EP1590352A1 (en) 2005-11-02
WO2004065391A1 (en) 2004-08-05
DE602004007239T2 (de) 2008-02-28
JP2006515604A (ja) 2006-06-01
ES2289475T3 (es) 2008-02-01
CN100582112C (zh) 2010-01-20
US20060229306A1 (en) 2006-10-12
DE602004007239D1 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
ES2217956B1 (es) Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2211344B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
CN106879256B (zh) 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用
KR20040106536A (ko) Ｐｄｅ４ 저해제로서의 피리다진-３(２ｈ)-온 유도체
CN111712491B (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
AU2019216247B2 (en) Inhibiting the transient receptor potential A1 ion channel
JP2006516653A (ja) キナーゼ阻害剤ピロロトリアジンの製造方法
ES2259891B1 (es) Nuevos derivados de piridotienopirimidina.
ES2259892B1 (es) Nuevos derivados de piridotienopirimidina.
ES2281251B1 (es) Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina.
TAN et al. Synthesis and evaluation of the analgesic activity of some new isoxazolo [4, 5-d] pyridazin-4 (5H)-one derivatives
JP3784868B2 (ja) 医薬用水和物

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20041101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2217956B1

Country of ref document: ES

PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20101018